Cancer Genetics Inc  

(Public, NASDAQ:CGIX)   Watch this stock  
Find more results for FRANKLYN G. PRENDERGAST
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 4.83 - 12.67
Open     -
Vol / Avg. 0.00/86,614.00
Mkt cap 100.83M
P/E     -
Div/yield     -
EPS -1.93
Shares 9.83M
Beta     -
Inst. own 14%
May 12, 2015
Q1 2015 Cancer Genetics Inc Earnings Call - Webcast
May 12, 2015
Q1 2015 Cancer Genetics Inc Earnings Release
Mar 12, 2015
Q4 2014 Cancer Genetics Inc Earnings Call - Webcast
Mar 12, 2015
Q4 2014 Cancer Genetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -97.89% -163.18%
Operating margin -95.01% -188.34%
EBITD margin - -180.11%
Return on average assets -38.01% -32.55%
Return on average equity -52.38% -41.60%
Employees 139 -
CDP Score - -


201 State Rt 17 Fl 2
RUTHERFORD, NJ 07070-2597
United States - Map
+1-201-5289200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cancer Genetics Inc. is engaged in the field of genomic-based cancer diagnostics. The products and services the Company is developing are poised to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs. It targets cancers where prognosis information is critical and where predicting treatment outcomes using available techniques is limited. These cancers include hematological, urogenital and HPV-associated cancers. The Company seeks to provide its tests and services to oncologists and pathologists at hospitals, cancer centers and physician offices, as well as to biopharmaceutical companies and clinical research organizations for their clinical trials. The Company’s services are performed at its laboratories located in New Jersey, North Carolina, Shanghai (China), and Hyderabad, India. Its laboratories comply with the highest regulatory standards as appropriate for the services they deliver including CLIA, CAP, NY State and NABL (India).

Officers and directors

John G. Pappajohn Chairman of the Board
Age: 86
Bio & Compensation  - Reuters
Panna L. Sharma President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Edward J. Sitar CPA Chief Financial Officer, Treasurer, Secretary
Age: 47
Bio & Compensation  - Reuters
Jane Houldsworth Ph.D. Vice President - Research & Development
Age: 56
Bio & Compensation  - Reuters
Raju S. K. Chaganti Ph.D. Director
Age: 82
Bio & Compensation  - Reuters
Edmund M. Cannon Independent Director
Age: 70
Bio & Compensation  - Reuters
Geoffrey Eric Harris Independent Director
Age: 53
Bio & Compensation  - Reuters
Howard McLeod Independent Director
Age: 49
Bio & Compensation  - Reuters
Franklyn G. Prendergast M.D., Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters